Abstract:TP53 mutation (TP53mut) associates with poor survival in AML patients. However, the risk of residual TP53mut has not fully characterized. We found there are around 3% of patients have detectable residual (less than 25%) TP53mut reads from TCGA AML patient exon sequencing data under current sequencing depth. Importantly, these patients also showed worse outcome as compared to the TP53 wild type patients. We therefore studied the effect of residual p53 mutation using two AML cell lines, OCI-AML2 and MV4-11. Both cell lines have been characterized as p53 wild type cells. However, a distinct p53 single hotspot mutation transcripts were detected in low frequency with RNA-seq analysis in both cells. TP53mut cells isolated from the parental cells show higher drug tolerance and have higher population of stem cell maker positive cells, a characteristic of chemoresistant cells. When mixed with p53 wild type cells, the TP53mut cells also show survival advantage under chemo-drug pressure in vitro and vivo (Fig. A), suggesting its advantage to become chemoresistant cells. Interestingly, the chemo-drug resistant cell lines derived from both lines have homogeneous TP53mut at same spot as parental residual mutation cells. Further, we found two p53 target genes p21 and GADD45A contribute to cell survival and chemoresistance. Decrease of these genes leads to cell less sensitive upon chemo-drug treatment. We previously showed that histone deacetylase inhibitor Romidepsin can resensitize chemoresistant cells. Here we further show that Romidepsin can reactivate p53 targeted genes which are failed to be activated by mutant p53 (Fig. B), including p21 and GADD45A, through increasing gene promotor histone acetylation. Moreover, it can preferentially target p53 mutant cell subpopulation (Fig. C). Therefore, either single treatment or combination with chemotherapy drug, Romidepsin can potentially cure or prevent residual p53 mutation caused chemoresistance and relapse in patient. Taking together, our study raise importance on previous under looked residual p53 mutation in AML patient and shed lights on therapeutic strategies for treatments on chemoresistance. Figure Disclosures No relevant conflicts of interest to declare.

Histone Deacetylase Inhibitor Targets CD123/CD47-positive Cells and Reverse Chemoresistance Phenotype in Acute Myeloid Leukemia

Targeting HDAC3, a New Partner Protein of AKT in the Reversal of Chemoresistance in Acute Myeloid Leukemia Via DNA Damage Response.

Targeting CaMKII-δ/DHCR24 Axis is a Novel Strategy Against Acute Myeloid Leukemia

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.

A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.

Residual TP53 Mutation Contributes to Chemoresistance Through Clonal Expansion in Acute Myeloid Leukemia

Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells

Simultaneous Inhibition of Mcl-1 and Induction of DNA Damage Accumulation by Chidamide, a Novel Selective HDACi, Potentiates the Cytotoxicity of ABT-199 in Acute Myeloid Leukemia

CD123 Antagonistic Peptides Assembled with Nanomicelles Act As Monotherapeutics to Combat Refractory Acute Myeloid Leukemia

Inhibition Of Histone Deacetylases 1 And 6 Enhances Ara-C-Induced Apoptosis In Pediatric Acute Myeloid Leukemia Cells

Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia

Single-cell Analysis Reveals the Chemotherapy-Induced Cellular Reprogramming and Novel Therapeutic Targets in Relapsed/refractory Acute Myeloid Leukemia

Synthetic Lethality of Combined AT-101 with Idarubicin in Acute Myeloid Leukemia Via Blockade of DNA Repair and Activation of Intrinsic Apoptotic Pathway.

Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports

Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines

Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia

Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia

Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma